Aprea Therapeutics, Inc.
APRE
$1.59
-$0.0324-2.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 205.80K | 354.60K | 561.60K | 380.60K | 14.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 205.80K | 354.60K | 561.60K | 380.60K | 14.10K |
| Cost of Revenue | 2.36M | 2.85M | 2.56M | 1.60M | 2.05M |
| Gross Profit | -2.15M | -2.49M | -2.00M | -1.22M | -2.03M |
| SG&A Expenses | 1.07M | 1.61M | 1.85M | 1.93M | 1.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.43M | 4.45M | 4.41M | 3.53M | 3.69M |
| Operating Income | -3.23M | -4.10M | -3.85M | -3.15M | -3.67M |
| Income Before Tax | -2.89M | -3.78M | -3.47M | -2.81M | -3.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.89M | -3.78M | -3.47M | -2.81M | -3.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.89M | -3.78M | -3.47M | -2.81M | -3.44M |
| EBIT | -3.23M | -4.10M | -3.85M | -3.15M | -3.67M |
| EBITDA | -3.22M | -4.09M | -3.84M | -3.14M | -3.67M |
| EPS Basic | -0.49 | -0.64 | -0.58 | -0.67 | -0.92 |
| Normalized Basic EPS | -0.30 | -0.40 | -0.37 | -0.42 | -0.58 |
| EPS Diluted | -0.49 | -0.64 | -0.58 | -0.67 | -0.92 |
| Normalized Diluted EPS | -0.30 | -0.40 | -0.37 | -0.42 | -0.58 |
| Average Basic Shares Outstanding | 5.95M | 5.94M | 5.94M | 4.20M | 3.74M |
| Average Diluted Shares Outstanding | 5.95M | 5.94M | 5.94M | 4.20M | 3.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |